Orai3 is significantly down-regulated and the decrease in Orai1:Orai3 ratio might reflect a different stoichiometry of Orai1/Orai3 subunits in CRAC channel that open the possibility for specific therapeutic targeting in prostate cancer. Here, ORAI1 is linked to Familial prostate cancer.